Journal
PSYCHIATRY RESEARCH
Volume 256, Issue -, Pages 365-370Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.psychres.2017.06.063
Keywords
Z-drugs; Eszopiclone; Alpidem; Schizophrenia; Meta-analysis; Systematic review
Categories
Funding
- Fujita Health University School of Medicine
- GlaxoSmithKline
- Meiji
- Otsuka
Ask authors/readers for more resources
No systematic reviews and meta-analyses on the use of Z-drug for schizophrenia are available. Randomized, placebo-controlled, or non-pharmacological intervention-controlled trials published before 03/20/2017 were retrieved from major healthcare databases and clinical trial registries. A meta-analysis including only randomized, placebo-controlled trials was performed. Efficacy outcomes were measured as improvement in overall schizophrenia symptoms, total sleep time, and wake after sleep onset. Safety/acceptability outcomes were discontinuation rate and individual adverse events. Four trials [1 alpidem placebo-controlled study (n = 66), 2 eszopiclone placebo-controlled studies (n = 60), and 1 eszopiclone, shallow needling-controlled study (n = 96)] were identified. The meta-analysis showed no significant differences in any outcome between pooled Z-drug and placebo treatment groups. For individual studies, alpidem was superior to placebo in improving the overall schizophrenia symptoms. One of the eszopiclone studies showed that eszopiclone was superior to placebo in improving the Insomnia Severity Index scores. Another eszopiclone study showed that eszopiclone did not differ from shallow needling therapy in improving both schizophrenia- and insomnia-related symptoms. Although this study failed to show significant benefits for the use of Z-drug in the treatment of schizophrenia, it showed that short-term use of eszopiclone is an acceptable method for treating persistent insomnia among these patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available